Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982;13(3):182-4.
doi: 10.1007/BF00205385.

A Follow-Up Study on Chemoimmunotherapy (5-fluorouracil and BCG) in Advanced Gastric Cancer

Clinical Trial

A Follow-Up Study on Chemoimmunotherapy (5-fluorouracil and BCG) in Advanced Gastric Cancer

T Popiela et al. Cancer Immunol Immunother. .

Abstract

Two hundred and seventeen patients with advanced gastric cancer were classified according to the resectability of the tumour into two groups: I, resectable (non-radical surgery), 99 patients, and II, non-resectable carcinoma, 118 patients. Within each group patients were randomly assigned to receive 5-fluorouracil (5-FU) + BCG, 5-FU, or no further treatment (surgery only). BCG was given by scarification. A 2-year follow-up is reported. The group of patients with resectable tumours and receiving chemoimmunotherapy had a statistically significant prolongation of survival compared with the 5-FU and surgery only groups. No differences in survival were observed between these treatment modalities in patients with non-resectable tumour. These observations indicate that chemoimmunotherapy may be of benefit for a selected group of patients with gastric cancer.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Dev Biol Stand. 1977 Apr 13-15;38:541-5 - PubMed
    1. Cancer. 1979 Apr;43(4):1314-9 - PubMed
    1. Cancer. 1979 Jul;44(1):42-7 - PubMed
    1. Surgery. 1979 May;85(5):509-13 - PubMed
    1. Hawaii Med J. 1977 Mar;36(3):71-3 - PubMed

Publication types

LinkOut - more resources

Feedback